PMID- 22579561
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20121127
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 12
IP  - 2
DP  - 2012 Dec
TI  - Intravenous immunoglobulin for the treatment of Crohn's disease.
PG  - 275-80
LID - S1568-9972(12)00096-1 [pii]
LID - 10.1016/j.autrev.2012.04.006 [doi]
AB  - Crohn's disease (CD) is a debilitating condition which still requires improvement 
      in its management. There is a need for alternatives to anti-tumour necrosis 
      factor drugs which are costly and beneficial in less than 50% of patients. 
      Intravenous immunoglobulin (IVIG) has been used in the management of 
      aminosalicylate- and steroid-resistant CD for more than 20 years, although the 
      published literature available is limited. A literature search identified 17 
      relevant publications since 1969, including five case reports of single patients, 
      two abstracts, three conference papers, one review paper and six book or journal 
      articles. No randomised controlled trials of IVIG in CD have been published. A 
      review of the evidence identified indicates that IVIG can induce a rapid and 
      significant improvement in aminosalicylate- and steroid-resistant CD, often 
      within days of the initial administration. Data from longer-term studies show 
      that maintenance of remission over the medium term is also possible. These 
      encouraging findings provide a rationale for the initiation of larger randomised 
      controlled trials of IVIG in CD with the aim of providing further treatment 
      options for this difficult-to-manage condition.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Rogosnitzky, Moshe
AU  - Rogosnitzky M
AD  - MedInsight Research Institute, P.O. Box 386, Telz Stone, 90840, Israel. 
      moshe@medinsight.org
FAU - Danks, Rachel
AU  - Danks R
FAU - Holt, Daniel
AU  - Holt D
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20120508
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Crohn Disease/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Immunologic Factors/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2012/05/15 06:00
MHDA- 2013/05/03 06:00
CRDT- 2012/05/15 06:00
PHST- 2012/04/12 00:00 [received]
PHST- 2012/04/28 00:00 [accepted]
PHST- 2012/05/15 06:00 [entrez]
PHST- 2012/05/15 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
AID - S1568-9972(12)00096-1 [pii]
AID - 10.1016/j.autrev.2012.04.006 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2012 Dec;12(2):275-80. doi: 10.1016/j.autrev.2012.04.006. Epub 
      2012 May 8.